Meet the Team
Behind the Technology.

  • Duke Rohlen
    Chief Executive Officer
    spirox_sitting_duke-101316

    Duke has over 20 years of executive experience in medical device companies. Prior to Spirox, he served as CEO of Advanced Cardiac Therapeutics, Founder and CEO of CV Ingenuity (acquired by Covidien/Medtronic), President of FoxHollow Technologies (acquired by ev3/Medtronic), entrepreneur-in-residence for Alta Partners, and in other senior management positions. Duke received an M.B.A. from Harvard Business School and a B.A. from Stanford University.

  • Neil Hattangadi, MD
    President & COO
    spirox_sitting_neil-101316

    Neil has over 15 years of executive experience in medical device companies. Prior to Spirox, he served as Executive Vice President and General Manager at Volcano Corporation (acquired by Royal Phillips), Investor with SAC Capital and Citadel, Vice President at FoxHollow Technologies (acquired by ev3/Medtronic), and a Consultant at McKinsey and Company. Neil received a B.S.E from Duke University, an M.Sc. from Oxford University as a Rhodes Scholar, and an M.D. from Harvard University.

  • Doug Koo
    Chief Financial Officer
    spirox_sitting_doug-101316

    Doug has over 22 years of experience, including Chief Financial Officer roles at CV Ingenuity (acquired by Covidien/Medtronic), Advanced Cardiac Therapeutics, and wine.com. He previously worked as a Consultant at Gemini Consulting. Doug received an M.B.A. from Stanford University and a B.S. from University of California San Diego.

  • Don Gonzales, MD
    Co-Founder, Chief Medical Officer
    spirox_sitting_don-101316

    Dr. Don Gonzales is a serial entrepreneur who founded several successful medical device companies in the ear, nose and throat space including Cryosa, Mimosa Medical, and ENTrigue Surgical (acquired by Arthrocare). He also performed cutting-edge research at the Cardiovascular Research Center at Massachusetts General Hospital, Memorial Sloan Kettering, Strang Cancer Institute at Rockefeller University, and Cornell University. Don graduated from Gordon College and Cornell University Medical College, then completed his residency in otolaryngology-head and neck surgery at Tulane University School of Medicine.

  • Mike Rosenthal
    Chief Strategic Officer & CTO
    spirox_sitting_mike-101316

    Mike brings over 20 years of Research & Development, Operations and Regulatory experience in medical device companies, including CardioGenesis, FoxHollow Technologies (acquired by ev3/Medtronic) and Sawtooth (acquired by Avinger). Mike has more than 50 allowed or pending patents applications in cardiovascular, tissue imaging, drug delivery, orthopedics, plastic/aesthetic, general surgery and ENT applications. He received a B.S.M.E. from Stanford University.

  • Bill Beasley
    SVP of Manufacturing & Operations
    spirox_sitting_beasley-101316

    Bill brings over 20 years of Operations experience, including executive roles at FoxHollow Technologies (acquired by ev3/Medtronic) and Neodyne Biosciences. He received a B.S. in Life Sciences from University of Notre Dame.

  • Scott Baron
    VP of Research & Development
    spirox_sitting_scott-101316

    Scott has over 19 years of Research & Development and Operations experience in medical device and engineering companies, including Acclarent (acquired by Johnson & Johnson), Abbott Vascular Devices, Axcelis Technologies and Lockheed Martin. Scott received a B.S.M.E. from Stanford University.

  • Matt Brokaw
    VP of Marketing & Commercial Operations
    spirox_sitting_matt-101316

    Matt brings over 15 years of Marketing and Sales experience in medical device companies, including Acclarent (acquired by Johnson & Johnson), Sonitus and Guidant. He received an M.B.A. from Stanford University and a B.A. from Williams.

  • Jack Dombroski
    VP of Commercial Operations
    spirox_sitting_jack-101316

    Jack brings over 20 years of experience in medical device commercial operations, including Covidien Vascular (acquired by Medtronic), FoxHollow Technologies (acquired by ev3/Medtronic) and Cordis Cardiology. He received a B.S.B.A. in Economics and Finance from Missouri Southern State University and a B.A. Communications from the University of Texas at Arlington.

  • Janie Mandrusov, PhD
    Senior Director of Clinical Affairs
    spirox_sitting_janie-101316

    Janie brings over 19 years of medical device research and clinical development experience, including leadership roles at SinuSys, ArthroCare (acquired by Smith & Nephew) and Guidant (acquired by Abbott). She received a B.S. in Bioengineering from University of California, San Diego and a Ph.D. in Chemical Engineering from Columbia University.

  • Mark Alley
    Director of Sales
    spirox_sitting_mark-101316

    Mark brings over 20 years of sales and sales executive experience, including leadership roles at Acclarent (acquired by Johnson & Johnson), Boston Scientific, Black & Decker, American Coatings and Armour Swift-Eckrich. He received a B.S. in Marketing from Butler University.

Advisors

Our Physician
Advisors.

Board & Investors

Our Board

  • Duke Rohlen

    Duke has over 20 years of executive experience in medical device companies. Prior to Spirox, he served as CEO of Advanced Cardiac Therapeutics, Founder and CEO of CV Ingenuity (acquired by Covidien/Medtronic), President of FoxHollow Technologies (acquired by ev3/Medtronic), entrepreneur-in-residence for Alta Partners, and in other senior management positions. Duke received an M.B.A. from Harvard Business School and a B.A. from Stanford University.

  • Aftab R. Kherani, MD

    Dr. Kherani joined Aisling Capital in 2008 and currently serves as a Partner. Previously, Dr. Kherani was an Engagement Manager at McKinsey & Company, where he was a member of the Pharmaceutical, Medical Product and Private Equity practices for two years. Prior to McKinsey, Dr. Kherani was a Chief Resident in General Surgery at Duke University Medical Center, and completed a two-year post-doctoral research fellowship at Columbia University, College of Physicians & Surgeons. Dr. Kherani received his M.D., B.S. in Biology, and A.B. in Economics from Duke University.

  • Ron Kuppersmith, MD, FACS

    Dr. Kuppersmith is an otolaryngologist-head and neck surgeon and a faculty member of the Texas A&M Health Science Center College of Medicine. He has served as the President of the American Academy of Otolaryngology-Head and Neck Surgery, as President of the Texas Association of Otolaryngology-Head and Neck Surgery, and on the Board of Trustees of the College Station Medical Center. Dr. Kuppersmith attended the University of Michigan in Ann Arbor for his undergraduate degree and for medical school, and completed his residency in Otolaryngology-Head and Neck Surgery at Baylor College of Medicine. He also received his M.B.A. from the University of Washington in Seattle.

  • Jim Momtazee

    Jim Momtazee joined KKR in 1996 and is Head of the Health Care industry team and on the Investment Committee of KKR’s Americas Private Equity business. He currently serves on the board of directors of Air Medical Group Holdings, Arbor Pharmaceuticals, BridgeBio, PRA Health Sciences and Signostics. He was also involved in the investments in HCA and Jazz Pharmaceuticals. Prior to joining KKR, Mr. Momtazee was with Donaldson, Lufkin & Jenrette where he worked on a broad range of corporate finance, mergers and acquisitions, and merchant banking transactions. He holds an A.B. and M.B.A from Stanford University.

  • Tony Natale, MD

    Dr. Natale is a General Partner at Aperture Venture Partners. He has invested across a number of therapeutic areas, and also has been a founder and director of several venture-backed life sciences companies. Dr. Natale trained in General Surgery and Otolaryngology/Head and Neck Surgery at the University of Connecticut and Hartford Hospital, and holds a B.A., Phi Beta Kappa, from the University of Virginia, an M.D. from the University of Florida College of Medicine and an M.B.A. from Yale University’s School of Management.

  • Camille Samuels

    Cami Samuels joined Venrock as a Partner in 2014 and focuses on healthcare with an emphasis on biotech and consumer health. Prior to Venrock, Cami was a Managing Director at Versant Ventures for a decade, and served as a board observer for several companies. Before Versant, she was responsible for business development at Tularik, worked in corporate development at Genzyme and Millennium Predictive Medicine, and was a management consultant to healthcare and biotech companies at LEK Consulting. Cami earned her Bachelor’s degree in Biology from Duke University and an M.B.A. from Harvard Business School, where she graduated as a Baker Scholar.

  • Stacy Enxing Seng

    Stacy Enxing Seng is a Member of the Board of Directors for Sonova Holding AG, Hill-Rom and Solace Therapeutics. Prior to the Medtronic acquisition of Covidien, Enxing Seng served as an Executive in Residence as well as the President, Vascular Therapies, for Covidien. Stacy joined Covidien in July 2010 through the $2.6B ev3 acquisition where she was a founding member and executive officer responsible for leading ev3’s Peripheral Vascular Division from inception. She has also held various positions at Boston Scientific Corporation, SCIMED Life Systems Inc., Baxter Healthcare and American Hospital Supply. Stacy received a M.B.A. from Harvard University and has a B.A from Michigan State University.

Our Investors